Astrazeneca Phar (ASTRAZEN)
FAST GROWERFairStock Score: 51/100 — MIXED
Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹8,449.4 |
| Market Cap | ₹22,122.5 Cr |
| P/E Ratio | 106.34 |
| ROCE | 33.4% |
| ROE | 26.08% |
| Dividend Yield | 0.36% |
| Profit Growth | 107.17% |
| Debt/Equity | 0.05 |
| Sales Growth | 34.49% |
| Free Cash Flow | ₹9,616 Cr |
| Promoter Holding | 75% |
| 52-Week Range | ₹7,551.5 — ₹10,691 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹308.14 |
Astrazeneca Phar trades with a P/E ratio of 106.34, ROCE of 33.4%, ROE of 26.08%, profit growth of 107.17%, debt-to-equity of 0.05. The FairStock Score of 51/100 suggests mixed fundamentals — some metrics look solid while others need improvement.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer